Recently Published Articles, Papers and Newsletters

"Issue 2," TTC,llc Newsletter, 2010

"Issue 1," TTC,llc Newsletter, 2010.

"Issue 3," TTC,llc Newsletter, 2009.

"Issue 2," TTC,llc Newsletter, 2009.

"Issue 1," TTC,llc Newsletter, 2009.

 

• Standard Of Care In Study Management. Glass H. Applied Clinical Trials. pp 36-42. July 2010
• Two Worlds, One Planet. Glass H. Inside Outsourcing. pp 46-52. November 2009
• How to Manage Clinical Grant Costs, Glass H & Hollander K. Scrip Magazine. October 2009
• What Bothers Clinical Investigators, Glass H. Good Clinical Practice Journal. pp. 21-23, July 2009
• CRO Selection & Management, Glass H. & Beaudry D. Applied Clinical Trials, pp.48-54, April 2009
• The World’s Your Clinical Research Oyster. Glass H. Scrip Magazine. April 2009
• Investigator Attitudes toward Participation in Contract Research Organization-Managed Clinical Studies: A Survey of US Clinical Investigators. Glass H. Pharmaceutical Medicine. 23 (2): 85-90. 2009
• Investigator Dissatisfaction with the Conduct of Clinical Trials. Glass H. The Monitor. 23(4): 58-62, 2009
• Study Conduct a Big Part of the Budget. Glass H. Applied Clinical Trials. P. 14, January 2009
• Refutable Rates. Glass H. Applied Clinical Trials. P. 14, April 2009
• Reporting Concerns. Applied Clinical Trials. P. 14, July 2009
• CRO Selection & Management. Glass H. and Beaudry D. Applied Clinical Trials. pp. 48-54, April 2009
• Managing Clinical Grant Costs. Glass H. and Hollander K. Contemporary Clinical Trials. February 2009. doi:10.1016/j.cct.2009.02.001
• Pressure Points on Industry Executives: What Lies Ahead? Glass H & Poli L. International Journal of Pharmaceutical and Healthcare Marketing. Vol. 3, Iss. 1, 2009.
• The Profile of the One-Time 1572 Investigator. Glass H. Contemporary Clinical Trials. Vol. 30, pp. 34-39, 2009. doi:10.1016/j.cct.2008.09.008
• Global Clinical Trial Insight from TTC. Glass H. Applied Clinical Trials. P.16, September 2008
• The Importance of Medical Innovation in an Investigator's Decision to Take Part in Clinical Trials. Glass H. Drug Information Journal. Vol. 42, pp. 537-543, 2008.
• Key Factors in CRO Selection. Glass H., Beaudry D. Applied Clinical Trials. pp. 52-60, April 2008.
• Grant Budgeting and Negotiating in India and China. Jankosky J., Jiang Y., Farwell T. Applied Clinical Trials. pp. 56-62, November 2007.
• The CRO Crop. Glass H. and Beaudry D. Inside Outsourcing. pp. 56-63, November 2007.
• Outlook for Outsourcing. Glass H. Good Clinical Practice Journal. pp. 21-24, November 2007.
• The Demographic, Practice, and Prescribing Characteristics of US Clinical Investigators. Glass H and Beaudry D. Drug Information Journal. Vol. 41 pp. 645-651. 2007.
• Understanding Site Performance Differences in Multinational Phase III Clinical Trials. Glass H and DiFrancesco J. International Journal of Pharmaceutical Medicine. 21 (4): 279-286, 2007.
• Connecting the Dots. Glass H and Poli L. Pharmaceutical Executive. pp. 56-58, January 2007.
• Profiles of Phase IV Investigators and Subsequent Prescribing of the Study Drug. Glass H and Dalton D. Journal of Pharmaceutical Marketing and Management. 17 (3/4): 3-17, 2006.
• What is a Fair Market Value? Glass H. Good Clinical Practice Journal. pp. 23-25, August 2006.
• The 'L' Factor. Glass H. Scrip Magazine. November 2005.
• The Marketplace for Clinical Grants. Glass H. The Monitor. 19(4): 69-74, 2005.
• Follow the Phase III Leader. Glass H and Stefanacci R. Scrip Magazine. April 2005.
• Post-Launch Clinical Investigator Drug Prescribing in the US: The Behavior of Clinical Trial Investigators after Participating in Phase III Clinical Trials. Glass H and Rosenthal B. International Journal of Pharmaceutical Medicine. 16(2): 97-104, 2005.
• The Dual Role of Company Prescribing Loyalty in New Drug Launches. Glass H and Poli L. Journal of Pharmaceutical Marketing and Management. 16(2), 2004.
• Physician Participation in Clinical Studies and Subsequent Prescribing of New Drugs. Corrigan M and Glass H. Pharmacy and Therapeutics. 30(1): 60-66, 2005.
• Demographic, Practice and Prescribing Characteristics of Physicians Who Are Early Adopters of New Drugs. Glass H and Rosenthal R. Pharmacy and Therapeutics. 29(11): 699-708, 2004.
• Researchers as Marketers: Strengthen Relationships With Phase III Investigators for More Successful New Product Launches. Glass H. Pharmaceutical Executive. June 2004.
• Physician Participation in Market Support Clinical Studies and Subsequent Prescribing Behavior. Glass H. Journal of Pharmaceutical Marketing and Management. 15(4): 3-16, 2004.
• Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Clinical Investigator Prescribing Behavior? Glass H. Disease Management. 7(1): 77-87, 2004.
• Patterns in Prescribing Behavior: The Potential Hidden Costs of Using CROs. Glass H. Drug Information Journal. 38: 105-112, 2004.
• Series of Regulatory Rulings Guide FDA Decision Making. Glass H. Drug Benefit Trends. Volume 15, October 2003; Supplement G. Presented in conjunction with: The 15th Annual Meeting of the Academy of Managed Care Pharmacy. April 10, 2003, Minneapolis, MN, USA.

contact reprints@ttc-llc.com for reprints of Published Papers